Cory Renauer
Value, research analyst, biotech, small-cap

Why Aegerion Is Worth 1,732 Times Sales

In the first quarter of 2013, Aegerion Pharmaceuticals (NASDAQ:AEGR) posted its first revenues ever. At its recent price of about $74, the company's shares are trading at about 1,732 times trailing twelve month sales. If you think that's a bit steep for a biotech with a single product, you're not alone.


Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.